| Name | Title | Contact Details |
|---|---|---|
Jennifer Newberger |
Vice President, Head of Regulatory Affairs and Compliance | Profile |
Affinium Pharmaceuticals , Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Signature Pharmacy is a Winter Park, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company`s Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.
Tweed and our sister company Tweed Farms are wholly owned subsidiaries of Tweed Marijuana Inc., traded on the TSX Venture Exchange as TWD. We are a Canadian company licensed under the Marihuana for Medical Purposes Regulations. We strive to supply a wide selection of marijuana, as diverse as the patients who trust us with their patronage.
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.